Wednesday, November 13, 2019

Avidity Biosciences Finds $100M In New Funding

La Jolla-based biotechnology developer Avidity Biosciences, which is developing treatments for rare muscle disorders and other diseases, has raised $100M in a Series C funding, according to the company this morning. According to Avidity, the funding was led by RTW Investments, and also included Cormorant Asset Management, LP, CureDuchenne, Logos Capit

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.